gavage with cabozantinib Search Results


byoral gavage with cabozantinib  (TargetMol)
94
TargetMol byoral gavage with cabozantinib
Byoral Gavage With Cabozantinib, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/byoral gavage with cabozantinib/product/TargetMol
Average 94 stars, based on 1 article reviews
byoral gavage with cabozantinib - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
cabozantinib  (ChemieTek LLC)
90
ChemieTek LLC cabozantinib
(A) Viability of human GIST cell lines treated with imatinib or <t>cabozantinib</t> at the indicated concentrations. Using nonlinear regression, IC50 values were calculated for imatinib and cabozantinib in GIST882 (80 vs. 30 nM), GIST-T1 (37 vs. 15 nM), and HG129 (38 vs. 14 nM) cells and for cabozantinib in HG209 (10 nM) cells. (B–E) NSG mice with established HG129 or HG209 subcutaneous xenografts tumors were treated for 15 days. Representative gross appearance of tumors (scale bar, 1 cm), tumor growth curves, and representative KIT and Ki67 immunohistochemistry (scale bar, 100 µM) are shown. n=3–9 mice per group. (F) KitV558del/+ mice were treated for 2 weeks and then tumors were weighed and (G) stained for KIT, Ki67, and CD31 (representative images, scale bar, 100 µM). n=6–7 mice per group. (H) KitV558del/+ mice were treated for 8 weeks, and tumors were stained for KIT and Ki67 (representative images, scale bar, 100 µM). n=2 mice per group. Data from A, F and G are representative of 3 independent experiments. Bars, mean ± SEM. *, p<0.05.
Cabozantinib, supplied by ChemieTek LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cabozantinib/product/ChemieTek LLC
Average 90 stars, based on 1 article reviews
cabozantinib - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


(A) Viability of human GIST cell lines treated with imatinib or cabozantinib at the indicated concentrations. Using nonlinear regression, IC50 values were calculated for imatinib and cabozantinib in GIST882 (80 vs. 30 nM), GIST-T1 (37 vs. 15 nM), and HG129 (38 vs. 14 nM) cells and for cabozantinib in HG209 (10 nM) cells. (B–E) NSG mice with established HG129 or HG209 subcutaneous xenografts tumors were treated for 15 days. Representative gross appearance of tumors (scale bar, 1 cm), tumor growth curves, and representative KIT and Ki67 immunohistochemistry (scale bar, 100 µM) are shown. n=3–9 mice per group. (F) KitV558del/+ mice were treated for 2 weeks and then tumors were weighed and (G) stained for KIT, Ki67, and CD31 (representative images, scale bar, 100 µM). n=6–7 mice per group. (H) KitV558del/+ mice were treated for 8 weeks, and tumors were stained for KIT and Ki67 (representative images, scale bar, 100 µM). n=2 mice per group. Data from A, F and G are representative of 3 independent experiments. Bars, mean ± SEM. *, p<0.05.

Journal: Cancer research

Article Title: Pharmacological inhibition of KIT activates MET signaling in gastrointestinal stromal tumors

doi: 10.1158/0008-5472.CAN-14-2564

Figure Lengend Snippet: (A) Viability of human GIST cell lines treated with imatinib or cabozantinib at the indicated concentrations. Using nonlinear regression, IC50 values were calculated for imatinib and cabozantinib in GIST882 (80 vs. 30 nM), GIST-T1 (37 vs. 15 nM), and HG129 (38 vs. 14 nM) cells and for cabozantinib in HG209 (10 nM) cells. (B–E) NSG mice with established HG129 or HG209 subcutaneous xenografts tumors were treated for 15 days. Representative gross appearance of tumors (scale bar, 1 cm), tumor growth curves, and representative KIT and Ki67 immunohistochemistry (scale bar, 100 µM) are shown. n=3–9 mice per group. (F) KitV558del/+ mice were treated for 2 weeks and then tumors were weighed and (G) stained for KIT, Ki67, and CD31 (representative images, scale bar, 100 µM). n=6–7 mice per group. (H) KitV558del/+ mice were treated for 8 weeks, and tumors were stained for KIT and Ki67 (representative images, scale bar, 100 µM). n=2 mice per group. Data from A, F and G are representative of 3 independent experiments. Bars, mean ± SEM. *, p<0.05.

Article Snippet: Imatinib (600 mg/L in drinking water), sunitinib (53.6 mg/kg daily gavage), crizotinib (60 mg/kg daily gavage), and cabozantinib (50 mg/kg daily gavage, ChemieTek) were administered.

Techniques: Immunohistochemistry, Staining